RET fusion occurs in 1.4% of NSCLCs and 1.7% of lung adenocarcinomas and has identifiable clinicopathologic characteristics, warranting further clinical consideration and targeted therapy investigation.

To our knowledge, this study represents the first comprehensive and concurrent analysis of major recurrent oncogenic mutations found in a large cohort of lung adenocarcinomas from East Asian never-smokers. Since drugs are now available that target mutant EGFR, HER2, and ALK, respectively, this result indicates that prospective mutation testing in these patients should successfully assign a targeted therapy in the majority of cases.

Background: Hexokinase 2 (HK2) is frequently overexpressed in malignant tumors. Results: miR-143 down-regulates HK2 and inhibits glucose metabolism and cancer progression. Conclusion: miR-143 is an essential regulator of cancer glycolysis via targeting HK2. Significance: Discovering the important role of miRNA in cancer metabolism may provide potential targets for cancer therapy.